Form 4: Design Therapeutics Director William Arsani Reports Sale of Shares

Director William Arsani reported the sale of Design Therapeutics (DSGN) common stock on August 9, 2024.

Summary

• On August 9, 2024, William Arsani, a director of Design Therapeutics, Inc. (DSGN), reported a transaction involving the company's common stock.
• The transaction involved the disposition of 814,874 shares of common stock at a price of $4.25 per share.
• Following the reported transaction, Arsani continues to indirectly own shares through Logos SPV I LP (1 share), Logos Opportunities Fund II, L.P. (1,217,627 shares), and Logos Global Master Fund LP (3,000,000 shares).

Sentiment

Score: 4

Explanation: The sentiment is neutral. It's a report of a stock sale by a director, which doesn't inherently indicate positive or negative sentiment. The disclaimer of beneficial ownership adds a layer of complexity, suggesting a potentially arms-length relationship.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Stakeholder Impact

• The sale of shares by a director could potentially influence investor sentiment, although the impact is likely to be minimal given the director's disclaimer of beneficial ownership.

Key Dates